Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:IVA NASDAQ:ORKA NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$10.46+0.8%$15.41$1.06▼$24.28$3.23B0.689.96 million shs4.33 million shsIVAInventiva$5.54-3.7%$5.67$2.85▼$7.98$839.22M0.7300,283 shs106,329 shsORKAOruka Therapeutics$63.18-2.3%$54.01$8.91▼$91.00$3.25B-0.22.40 million shs947,406 shsTNGXTango Therapeutics$25.51+8.6%$21.14$1.25▼$28.41$3.39B1.222.93 million shs3.30 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+0.77%-4.04%-35.87%-15.03%+686.47%IVAInventiva-3.65%+2.59%+10.58%-10.65%+54.75%ORKAOruka Therapeutics-2.27%-9.47%+2.93%+93.57%+556.76%TNGXTango Therapeutics+8.55%+8.00%+18.32%+101.34%+1,722.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$10.46+0.8%$15.41$1.06▼$24.28$3.23B0.689.96 million shs4.33 million shsIVAInventiva$5.54-3.7%$5.67$2.85▼$7.98$839.22M0.7300,283 shs106,329 shsORKAOruka Therapeutics$63.18-2.3%$54.01$8.91▼$91.00$3.25B-0.22.40 million shs947,406 shsTNGXTango Therapeutics$25.51+8.6%$21.14$1.25▼$28.41$3.39B1.222.93 million shs3.30 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+0.77%-4.04%-35.87%-15.03%+686.47%IVAInventiva-3.65%+2.59%+10.58%-10.65%+54.75%ORKAOruka Therapeutics-2.27%-9.47%+2.93%+93.57%+556.76%TNGXTango Therapeutics+8.55%+8.00%+18.32%+101.34%+1,722.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 2.50Moderate Buy$18.7579.25% UpsideIVAInventiva 3.10Buy$16.56198.84% UpsideORKAOruka Therapeutics 2.82Moderate Buy$120.8091.20% UpsideTNGXTango Therapeutics 2.77Moderate Buy$22.44-12.02% DownsideCurrent Analyst Ratings BreakdownLatest IVA, TNGX, ORKA, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026ERASErasca MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$28.00 ➝ $26.005/11/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/28/2026ORKAOruka Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $100.004/27/2026ORKAOruka Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.004/27/2026ORKAOruka Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $160.004/27/2026ORKAOruka Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$200.004/27/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $151.004/27/2026TNGXTango Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/27/2026ERASErasca Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $30.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.27 per shareN/AIVAInventiva$5.07M159.48N/AN/A($0.22) per share-25.18ORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/ATNGXTango Therapeutics$62.38M58.99N/AN/A$2.57 per share9.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%N/AIVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/AN/AORKAOruka Therapeutics-$105.43M-$1.86N/AN/AN/AN/A-25.48%-24.34%N/ATNGXTango Therapeutics-$101.59M-$0.87N/AN/AN/A-151.15%-50.30%-36.25%N/ALatest IVA, TNGX, ORKA, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52-$0.48+$0.04-$0.48N/AN/A5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A3/30/2026Q4 2025IVAInventiva-$0.18-$0.7480-$0.5680-$0.16$8.67 million$0.01 million3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/A3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/A3/5/2026Q4 2025TNGXTango Therapeutics-$0.31-$0.29+$0.02-$0.29$0.56 millionN/A2/15/2026Q4 2025 TUIVAInventivaN/A-$0.16N/A-$0.16N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A9.5210.04IVAInventivaN/A3.163.16ORKAOruka TherapeuticsN/A22.3722.37TNGXTango TherapeuticsN/A16.3216.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%IVAInventiva19.06%ORKAOruka Therapeutics56.44%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipERASErasca14.20%IVAInventiva32.00%ORKAOruka Therapeutics23.49%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120310.98 million266.81 millionOptionableIVAInventiva100145.95 million99.25 millionNot OptionableORKAOruka TherapeuticsN/A50.20 million38.41 millionN/ATNGXTango Therapeutics90144.24 million134.87 millionOptionableIVA, TNGX, ORKA, and ERAS HeadlinesRecent News About These CompaniesTango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsMay 13 at 4:07 PM | globenewswire.comStifel Remains Bullish on Tango Therapeutics (TNGX)May 10, 2026 | insidermonkey.comTango Therapeutics (NASDAQ:TNGX) Insider Sells $573,210.00 in StockMay 8, 2026 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 SharesMay 6, 2026 | insidertrades.comAdam Crystal Sells 27,000 Shares of Tango Therapeutics (NASDAQ:TNGX) StockMay 5, 2026 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Up 7.1% - Time to Buy?May 4, 2026 | marketbeat.comTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comTango Therapeutics (TNGX) Expected to Announce Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comWhy this CEO is confident his drug can top 'unprecedented' pancreatic cancer resultsApril 30, 2026 | msn.comTango Therapeutics (NASDAQ:TNGX) Trading Down 9.7% - Here's What HappenedApril 29, 2026 | marketbeat.comTango Therapeutics (TNGX) price target increased by 11.68% to 24.38April 28, 2026 | msn.comStifel Nicolaus Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock PriceApril 27, 2026 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 25, 2026 | marketbeat.com354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham IncApril 21, 2026 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year High - Should You Buy?April 20, 2026 | marketbeat.comIs Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?April 20, 2026 | finance.yahoo.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 38,460 SharesApril 17, 2026 | insidertrades.comInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 38,460 Shares of StockApril 16, 2026 | marketbeat.comTango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatApril 16, 2026 | finanznachrichten.deTudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGXApril 16, 2026 | marketbeat.comTango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatApril 15, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Quiet Infrastructure Play on Small-Bank SurvivalBy Peter Frank | April 21, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 2026Joby’s Stock Just Got Its Wings Over New York CityBy Jeffrey Neal Johnson | April 28, 2026Norwegian Cruise Line Cuts Outlook as Headwinds BuildBy Jennifer Ryan Woods | May 5, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026IVA, TNGX, ORKA, and ERAS Company DescriptionsErasca NASDAQ:ERAS$10.46 +0.08 (+0.77%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$10.22 -0.24 (-2.25%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Inventiva NASDAQ:IVA$5.54 -0.21 (-3.65%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$5.64 +0.11 (+1.90%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Oruka Therapeutics NASDAQ:ORKA$63.18 -1.47 (-2.27%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$66.00 +2.82 (+4.46%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Tango Therapeutics NASDAQ:TNGX$25.51 +2.01 (+8.55%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$24.39 -1.12 (-4.38%) As of 06:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
